Gotion, Inc., a Chinese company and U.S. subsidiary of Guoxuan High-Tech, announced a lithium battery plant in Illinois that is expected to open next year. This CCP-tied battery company is expected to benefit from green-energy tax breaks under the Democrats’ Inflation...
U.S. Senator Marco Rubio (R-FL) joined National Public Radio’s All Things Considered to discuss his plan to expand the child tax credit for working families. See below for the full transcript and listen to the edited interview here. On the connection between the child...
U.S. Senator Marco Rubio (R-FL) joined Wake Up America to discuss the U.S. House of Representatives’ impeachment inquiry and the hypocritical reaction by Democrats. See below for highlights and watch the full interview on YouTube and Rumble. On the U.S. House of...
Russia must face severe consequences for its unjustified and unprovoked invasion of Ukraine. Moscow continues to have open access to critical U.S. capital, which fuels Putin and his criminal war machine, through state-controlled and state-owned companies such as...
U.S. Senators Marco Rubio (R-FL) and Alex Padilla (D-CA) issued a joint statement condemning Azerbaijan’s unprovoked and unjustified military incursion in the South Caucasus against Armenians under the false pretext of leading an 'anti-terrorist operation' and in...
Vice Chairman of the Senate Select Committee on Intelligence Marco Rubio (R-FL) questioned witnesses at a hearing on the intersection of artificial intelligence (AI) and national security. Witnesses: Dr. Benjamin Jensen, Senior Fellow, CSIS and Professor, Marine...
Rubio Seeks Answers on Pharmacy Distribution of Abortion Drug
On January 3, 2023, the U.S. Food and Drug Administration (FDA) posted a new policy that allows pharmacies to distribute the chemical abortion pill mifepristone and remove the in-person distribution requirement. Data shows mifepristone is dangerous, which is why women using the drug to induce a chemical abortion were previously required to have medical supervision.
U.S. Senator Marco Rubio (R-FL) and Representative Andrew Clyde (R-GA) sent a letter to Government Accountability Office (GAO) Comptroller General Gene Dodaro urging the GAO to evaluate if the FDA’s change in guidance is considered a “rule” and subject to Congressional review under the Congressional Review Act.
- “We write to seek your review of whether the January 2023 REMS Modification for mifepristone, issued by the FDA, constitutes a ‘rule’ for purposes of the Congressional Review Act (CRA).”
- “The FDA’s update appears to prescribe detailed policy. For these reasons, we respectfully request a determination as to whether or not this ‘rule’ is applicable under the CRA. Please respond with your determination by February 14, 2023.”
Senators Cindy Hyde-Smith (R-MS), Mike Lee (R-UT), Thom Tillis (R-NC), Roger Marshall (R-KS), Mike Braun (R-IN), Rick Scott (R-FL), Roger Wicker (R-MS) and 27 members of the House also signed the letter.
Want more? The full text of the letter is below.
Dear Comptroller General Dodaro:
On January 3, 2023, the U.S. Food & Drug Administration (FDA) posted a new policy that increases access and consumption of mifepristone. We write to seek your review of whether the January 2023 REMS Modification for mifepristone, issued by the FDA, constitutes a “rule” for purposes of the Congressional Review Act (CRA).
With limited exceptions, the CRA defines a “rule” as follows:
‘[R]ule’ means the whole or part of an agency statement of general or particular applicability and future effect designed to implement, interpret, or prescribe law or policy or describing the organization, procedure, or practice requirements of an agency and includes the approval or prescription for the future of rates, wages, corporate or financial structures or reorganizations thereof, prices, facilities, appliances, services or allowances therefor or of valuations, costs, or accounting, or practices bearing on any of the foregoing.”
Based upon this broad definition, the Government Accountability Office has rightly pointed out that “agency pronouncements may be rules within the definition of 5 U.S.C. § 551 and the CRA, even if they are not subject to notice and comment rulemaking requirements under section 553.”
The FDA’s update appears to prescribe detailed policy. For these reasons, we respectfully request a determination as to whether or not this “rule” is applicable under the CRA. Please respond with your determination by February 14, 2023.